{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T17:23:06Z","timestamp":1783876986379,"version":"3.55.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"12","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci. China Life Sci."],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1007\/s11427-015-4974-5","type":"journal-article","created":{"date-parts":[[2015,11,20]],"date-time":"2015-11-20T15:10:13Z","timestamp":1448032213000},"page":"1302-1305","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The priming induction regimen of HAG as a low dose chemotherapy strategy in AML clonal evolution"],"prefix":"10.1007","volume":"58","author":[{"given":"AiLi","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JingYi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ShaoYan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian-Fei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,11,20]]},"reference":[{"key":"4974_CR1","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.molonc.2014.06.005","volume":"8","author":"RA Burrell","year":"2014","unstructured":"Burrell RA, Swanton C. Tumour heterogeneity and the evolution of polyclonal drug resistance. Mol Oncol 2014, 8: 1095\u20131111","journal-title":"Mol Oncol"},{"key":"4974_CR2","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/nature10738","volume":"481","author":"L Ding","year":"2012","unstructured":"Ding L, Ley TJ, Larson DE, Miller CA, Koboldt DC, Welch JS, Ritchey JK, Young MA, Lamprecht T, McLellan MD, McMichael JF, Wallis JW, Lu C, Shen D, Harris CC, Dooling DJ, Fulton RS, Fulton LL, Chen K, Schmidt H, Kalicki-Veizer J, Magrini VJ, Cook L, McGrath SD, Vickery TL, Wendl MC, Heath S, Watson MA, Link DC, Tomasson MH, Shannon WD, Payton JE, Kulkarni S, Westervelt P, Walter MJ, Graubert TA, Mardis ER, Wilson RK, DiPersio JF. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 2012, 481: 506\u2013510","journal-title":"Nature"},{"key":"4974_CR3","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nature11219","volume":"486","author":"L J Diaz","year":"2012","unstructured":"Diaz LA Jr, Williams RT, Wu J, Kinde I, Hecht JR, Berlin J, Allen B, Bozic I, Reiter JG, Nowak MA, Kinzler KW, Oliner KS, Vogelstein B. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 2012, 486: 537\u2013540","journal-title":"Nature"},{"key":"4974_CR4","first-page":"10","volume":"9","author":"K Yamada","year":"1995","unstructured":"Yamada K, Furusawa S, Saito K, Waga K, Koike T, Arimura H, Aoyagi A, Yamato H, Sakuma H, Tsunogake S. Concurrent use of granulocyte colony-stimulating factor with low-dose cytosine arabinoside and aclarubicin for previously treated acute myelogenous leukemia: a pilot study. Leukemia 1995, 9: 10\u201314","journal-title":"Leukemia"},{"key":"4974_CR5","first-page":"238","volume":"71","author":"K Saito","year":"2000","unstructured":"Saito K, Nakamura Y, Aoyagi M, Waga K, Yamamoto K, Aoyagi A, Inoue F, Nakamura Y, Arai Y, Tadokoro J, Handa T, Tsurumi S, Arai H, Kawagoe Y, Gunnji H, Kitsukawa Y, Takahashi W, Furusawa S. Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) for previously treated patients with relapsed or primary resistant acute myelogenous leukemia (AML) and previously untreated elderly patients with AML, secondary AML, and refractory anemia with excess blasts in transformation. Int J Hematol 2000, 71: 238\u2013244","journal-title":"Int J Hematol"},{"key":"4974_CR6","doi-asserted-by":"crossref","first-page":"6448","DOI":"10.18632\/oncotarget.3361","volume":"6","author":"J Li","year":"2015","unstructured":"Li J, Chen Y, Zhu Y, Zhou J, Xu Y, Li Y, Yu K, Pan L, Wang J, Ding J, Gu J, Zhou S, Shi J, Hong M, Xu J, Pan L, Duan L, Zhang R, Zhang S, Zhu H, Lu H, Liu P, Qiu H, Wu H, Qian S. Efficacy and safety of decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin in newly diagnosed elderly patients with acute myeloid leukemia. Oncotarget 2015, 6: 6448\u20136458","journal-title":"Oncotarget"},{"key":"4974_CR7","doi-asserted-by":"crossref","first-page":"4894","DOI":"10.1158\/0008-5472.CAN-08-3658","volume":"69","author":"RA Gatenby","year":"2009","unstructured":"Gatenby RA, Silva AS, Gillies RJ, Frieden BR. Adaptive therapy. Cancer Res 2009, 69: 4894\u20134903","journal-title":"Cancer Res"},{"key":"4974_CR8","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.jtbi.2013.06.036","volume":"335","author":"S Benzekry","year":"2013","unstructured":"Benzekry S, Hahnfeldt P. Maximum tolerated dose versus metronomic scheduling in the treatment of metastatic cancers. J Theor Biol 2013, 335: 235\u2013244","journal-title":"J Theor Biol"},{"key":"4974_CR9","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1089\/scd.2011.0267","volume":"21","author":"SC Li","year":"2012","unstructured":"Li SC, Lee KL, Luo J. Control dominating subclones for managing cancer progression and posttreatment recurrence by subclonal switchboard signal: implication for new therapies. Stem Cells Dev 2012, 21: 503\u2013506","journal-title":"Stem Cells Dev"},{"key":"4974_CR10","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.leukres.2015.04.002","volume":"39","author":"A Emadi","year":"2015","unstructured":"Emadi A, Sadowska M, Carter-Cooper B, Bhatnagar V, van der Merwe I, Levis MJ, Sausville EA, Lapidus RG. Perturbation of cellular oxidative state induced by dichloroacetate and arsenic trioxide for treatment of acute myeloid leukemia. Leuk Res 2015, 39: 719\u2013729","journal-title":"Leuk Res"}],"container-title":["Science China Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11427-015-4974-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T18:59:06Z","timestamp":1567364346000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11427-015-4974-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,20]]},"references-count":10,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["4974"],"URL":"https:\/\/doi.org\/10.1007\/s11427-015-4974-5","relation":{},"ISSN":["1674-7305","1869-1889"],"issn-type":[{"value":"1674-7305","type":"print"},{"value":"1869-1889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,20]]}}}